[
    [
        {
            "time": "2018-03-15",
            "original_text": "52-Week Company Lows",
            "features": {
                "keywords": [
                    "52-Week",
                    "Company",
                    "Lows"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "52-Week Company Lows",
                "Correlation": 6,
                "Sentiment": 2,
                "Importance": 5,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-04-10",
            "original_text": "Thermo Fisher Closes API Site Buyout, Fortifies Pharma Unit",
            "features": {
                "keywords": [
                    "Thermo Fisher",
                    "Closes",
                    "API",
                    "Site",
                    "Buyout",
                    "Fortifies",
                    "Pharma",
                    "Unit"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Thermo Fisher Closes API Site Buyout, Fortifies Pharma Unit",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-05-20",
            "original_text": "Novo Nordisk Focuses on Pipeline Development Amid Competition",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Focuses",
                    "Pipeline",
                    "Development",
                    "Amid",
                    "Competition"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Novo Nordisk Focuses on Pipeline Development Amid Competition",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-06-15",
            "original_text": "Lilly's CYRAMZA® (ramucirumab) Phase 3 Data in First-Line EGFR-Mutated Non-Small Cell Lung Cancer Published in The Lancet Oncology",
            "features": {
                "keywords": [
                    "Lilly",
                    "CYRAMZA",
                    "Phase",
                    "3",
                    "Data",
                    "First-Line",
                    "EGFR-Mutated",
                    "Non-Small",
                    "Cell",
                    "Lung",
                    "Cancer",
                    "Published",
                    "The",
                    "Lancet",
                    "Oncology"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "oncology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly's CYRAMZA® (ramucirumab) Phase 3 Data in First-Line EGFR-Mutated Non-Small Cell Lung Cancer Published in The Lancet Oncology",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-07-05",
            "original_text": "FDA approves Pfenex's osteoporosis therapy",
            "features": {
                "keywords": [
                    "FDA",
                    "approves",
                    "Pfenex",
                    "osteoporosis",
                    "therapy"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "FDA approves Pfenex's osteoporosis therapy",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 10
            }
        }
    ]
]